GILD
Gilead Sciences develops and markets pharmaceutical treatments across multiple therapeutic areas, including antiviral drugs for HIV and hepatitis C, oncology therapies, and other disease categories. The company operates both marketed drugs and pipeline programs, with a portfolio spanning from approved medications like Biktarvy and Harvoni to cell therapy products like Yescarta and investigational candidates such as Jyseleca. Gilead's development stage ranges from commercial-stage products generating revenue to earlier-stage pipeline programs in development.
Pipeline
BIKTARVY is a fixed dose combination of antiretroviral drugs bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) [see Microbiology (12.4) ] .
Oral 5-fluorouracil prodrug activated to 5-FU in tumor tissue. Used in colorectal, breast, and gastric cancers, often combined with oxaliplatin or platinum.
Platinum-based chemotherapy that forms DNA crosslinks, inducing apoptosis in cancer cells. Standard of care across many solid tumors including NSCLC, ovarian, breast, bladder, and biliary cancers.
Platinum-based chemotherapy that forms DNA crosslinks. Foundational cytotoxic agent used across testicular, bladder, ovarian, head and neck, and lung cancers.
Taxane chemotherapy that stabilizes microtubules and arrests mitosis. Used in breast, prostate, NSCLC, head and neck, and gastric cancers.
Anthracycline chemotherapy that intercalates DNA and inhibits topoisomerase II. Backbone agent in breast cancer, lymphoma, leukemia, and sarcoma regimens.
Pyrimidine nucleoside analog chemotherapy that incorporates into DNA and inhibits ribonucleotide reductase. First-line in pancreatic cancer; used in lung, breast, and bladder cancers.
YEZTUGO is an HIV-1 antiretroviral agent with long-acting properties [see Microbiology (12.4) ].
Albumin-bound paclitaxel (Abraxane) with improved delivery and reduced solvent toxicity. Used in metastatic breast cancer, NSCLC, and pancreatic adenocarcinoma.
Taxane chemotherapy that binds β-tubulin and prevents microtubule depolymerization, causing mitotic arrest. Used in breast, ovarian, lung, and other cancers.
Anti-PD-1 monoclonal antibody (Keytruda) that blocks the PD-1 checkpoint, restoring anti-tumor immune response. FDA-approved across many cancers including NSCLC, melanoma, and gastroesophageal cancer.
Multi-targeted antifolate chemotherapy used in non-squamous NSCLC and mesothelioma, typically combined with platinum agents.
Anti-TROP2 antibody (Trodelvy) conjugated to SN-38, a topoisomerase I inhibitor. Approved in metastatic triple-negative breast cancer, HR+/HER2- breast cancer, and urothelial carcinoma.
Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. However, the mechanism by which seladelpar exerts its therapeutic effects in patients with PBC is not well understood.
Topoisomerase I inhibitor chemotherapy used in small cell lung cancer, ovarian cancer, and cervical cancer.
PREZCOBIX is a fixed-dose combination of an HIV-1 antiviral drug, darunavir and a CYP3A inhibitor, cobicistat [see Microbiology (12.4) ].
PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment.
Enfortumab vedotin-ejfv is an ADC. The antibody is a human IgG1 kappa directed against Nectin-4, an adhesion protein located on the surface of cells. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker.
Anti-PD-1 monoclonal antibody (Opdivo) that blocks the PD-1 checkpoint. Approved across melanoma, NSCLC, RCC, head and neck, hepatocellular, and other cancers.